{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:36:29Z","timestamp":1787027789049,"version":"build-2736575974"},"reference-count":120,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2023,12,10]],"date-time":"2023-12-10T00:00:00Z","timestamp":1702166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Malignant neoplasms are currently one of the leading causes of morbidity and mortality worldwide, posing a major public health challenge. However, recent advances in research in cancer biology and immunity have led to the development of immunotherapy, which is now used on an everyday basis in cancer treatment in addition to surgical treatment, classical cytostatics, and radiotherapy. The efficacy of immunotherapy has promoted the great popularity of this treatment among patients, as well as significant research interest. The increasing number of patients being treated with immunotherapy not only reassures physicians of the efficacy of this technique but also shows the wide spectrum of side effects of this therapy, which has not been considered before. Immune-related adverse events may affect many systems and organs, such as digestive, cardiovascular, respiratory, skin, or endocrine organs. Most complications have a mild or moderate course, but there are life-threatening manifestations that are essential to be aware of because if they are not properly diagnosed and treated on time, they can have fatal consequences. The purpose of this paper was to present the results of a literature review on the current state of knowledge on life-threatening endocrine side effects (such as adrenal crisis, thyroid storm, myxoedema crisis, diabetic ketoacidosis, and severe hypocalcaemia) of immune checkpoint inhibitors to provide information on symptoms, diagnostics, and management strategies.<\/jats:p>","DOI":"10.3390\/cancers15245786","type":"journal-article","created":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T13:18:21Z","timestamp":1702300701000},"page":"5786","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Life-Threatening Endocrinological Immune-Related Adverse Events of Immune Checkpoint Inhibitor Therapy"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-8852-0918","authenticated-orcid":false,"given":"Aleksandra","family":"Basek","sequence":"first","affiliation":[{"name":"Student Research Group, Department and Clinic of Internal Medicine, Angiology, and Physical Medicine, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Batorego 15 St., 41-902 Bytom, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0039-8306","authenticated-orcid":false,"given":"Grzegorz K.","family":"Jakubiak","sequence":"additional","affiliation":[{"name":"Department and Clinic of Internal Medicine, Angiology, and Physical Medicine, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Batorego 15 St., 41-902 Bytom, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2210-8744","authenticated-orcid":false,"given":"Grzegorz","family":"Cie\u015blar","sequence":"additional","affiliation":[{"name":"Department and Clinic of Internal Medicine, Angiology, and Physical Medicine, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Batorego 15 St., 41-902 Bytom, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6939-9898","authenticated-orcid":false,"given":"Agata","family":"Stanek","sequence":"additional","affiliation":[{"name":"Department and Clinic of Internal Medicine, Angiology, and Physical Medicine, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Batorego 15 St., 41-902 Bytom, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,12,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/s41571-021-00514-z","article-title":"Planning for tomorrow: Global cancer incidence and the role of prevention 2020\u20132070","volume":"18","author":"Soerjomataram","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Jakubiak, G.K., Pawlas, N., Cie\u015blar, G., and Stanek, A. (2021). Pathogenesis and clinical significance of in-stent restenosis in patients with diabetes. Int. J. Environ. Res. Public Health, 18.","DOI":"10.3390\/ijerph182211970"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Mu\u0107ka, S., Miodo\u0144ska, M., Jakubiak, G.K., Starzak, M., Cie\u015blar, G., and Stanek, A. (2022). Endothelial function assessment by flow-mediated dilation method: A valuable tool in the evaluation of the cardiovascular system. Int. J. Environ. Res. Public Health, 19.","DOI":"10.3390\/ijerph191811242"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Finocchario-Kessler, S., Wexler, C., Maloba, M., Mabachi, N., Ndikum-Moffor, F., and Bukusi, E. (2016). Cervical cancer prevention and treatment research in Africa: A systematic review from a public health perspective. BMC Womens Health, 16.","DOI":"10.1186\/s12905-016-0306-6"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"E59","DOI":"10.5888\/pcd18.210006","article-title":"Cancer incidence projections in the United States between 2015 and 2050","volume":"18","author":"Weir","year":"2021","journal-title":"Prev. Chronic Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejca.2020.01.011","article-title":"The cost of cancer in Europe 2018","volume":"129","author":"Hofmarcher","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ejca.2021.07.012","article-title":"Gastrointestinal cancer classification and prognostication from histology using deep learning: Systematic review","volume":"155","author":"Kuntz","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2021.06.027","article-title":"Advances in the epidemiology of pancreatic cancer: Trends, risk factors, screening, and prognosis","volume":"520","author":"Cai","year":"2021","journal-title":"Cancer Lett."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1002\/cam4.4551","article-title":"Global burden of primary liver cancer by five etiologies and global prediction by 2035 based on global burden of disease study 2019","volume":"11","author":"Liu","year":"2022","journal-title":"Cancer Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ccm.2019.10.001","article-title":"Lung cancer 2020: Epidemiology, etiology, and prevention","volume":"41","author":"Bade","year":"2020","journal-title":"Clin. Chest Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.eururo.2023.04.021","article-title":"2022 update on prostate cancer epidemiology and risk factors-a systematic review","volume":"84","author":"Bergengren","year":"2023","journal-title":"Eur. Urol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/GRF.0000000000000721","article-title":"Breast cancer epidemiology and contemporary breast cancer care: A review of the literature and clinical applications","volume":"65","author":"Phadke","year":"2022","journal-title":"Clin. Obstet. Gynecol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"967","DOI":"10.36740\/WLek202005124","article-title":"Cancer of the organs of the reproductive system in women with type 2 diabetes. effects of antidiabetic therapy","volume":"73","author":"Vatseba","year":"2020","journal-title":"Wiad. Lek."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"598100","DOI":"10.3389\/fchem.2020.598100","article-title":"Moving beyond the pillars of cancer treatment: Perspectives from nanotechnology","volume":"8","author":"Siamof","year":"2020","journal-title":"Front. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3389\/fphar.2018.00245","article-title":"Editorial: Adverse effects of cancer chemotherapy: Anything new to improve tolerance and reduce sequelae?","volume":"9","author":"Nurgali","year":"2018","journal-title":"Front. Pharmacol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Pansy, K., Uhl, B., Krstic, J., Szmyra, M., Fechter, K., Santiso, A., Th\u00fcminger, L., Greinix, H., Kargl, J., and Prochazka, K. (2021). Immune regulatory processes of the tumor microenvironment under malignant conditions. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222413311"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/ni.2703","article-title":"Innate and adaptive immune cells in the tumor microenvironment","volume":"14","author":"Gajewski","year":"2013","journal-title":"Nat. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13045-021-01103-4","article-title":"Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response","volume":"14","author":"Fu","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"150923","DOI":"10.1016\/j.soncn.2019.08.002","article-title":"Cancer and the immune system: The history and background of immunotherapy","volume":"35","author":"Abbott","year":"2019","journal-title":"Semin. Oncol. Nurs."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3322\/caac.21596","article-title":"A review of cancer immunotherapy toxicity","volume":"70","author":"Kennedy","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine toxicity of cancer immunotherapy targeting immune checkpoints","volume":"40","author":"Chang","year":"2019","journal-title":"Endocr. Rev."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1084\/jem.20090847","article-title":"PD-L1 regulates the development, maintenance, and function of induced regulatory T cells","volume":"206","author":"Francisco","year":"2009","journal-title":"J. Exp. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1093\/annonc\/mdt291","article-title":"Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20)","volume":"24","author":"McDermott","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1158\/1078-0432.CCR-11-1823","article-title":"CTLA-4 blockade with ipilimumab: Long-term follow-up of 177 patients with metastatic melanoma","volume":"18","author":"Prieto","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nri2326","article-title":"Inhibitory B7-family molecules in the tumour microenvironment","volume":"8","author":"Zou","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1182\/blood-2008-12-195792","article-title":"Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired","volume":"114","author":"Ahmadzadeh","year":"2009","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"12293","DOI":"10.1073\/pnas.192461099","article-title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade","volume":"99","author":"Iwai","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.18632\/oncotarget.2980","article-title":"PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma","volume":"6","author":"Luke","year":"2015","journal-title":"Oncotarget"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1200\/JCO.22.02270","article-title":"Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates","volume":"41","author":"Brahmer","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/annonc\/mdz011","article-title":"Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001","volume":"30","author":"Hamid","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"687","DOI":"10.2217\/fon-2018-0405","article-title":"JAVELIN Head and Neck 100: A Phase III trial of avelumab and chemoradiation for locally advanced head and neck cancer","volume":"15","author":"Yu","year":"2019","journal-title":"Future Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e000957","DOI":"10.1136\/jitc-2020-000957","article-title":"TIGIT in cancer immunotherapy","volume":"8","author":"Chauvin","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/cei.13407","article-title":"TIGIT as an emerging immune checkpoint","volume":"200","author":"Guillerey","year":"2020","journal-title":"Clin. Exp. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"871085","DOI":"10.3389\/fonc.2022.871085","article-title":"Update in TIGIT immune-checkpoint role in cancer","volume":"12","author":"Annese","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3892\/or.2021.7943","article-title":"CD155\/TIGIT, a novel immune checkpoint in human cancers (Review)","volume":"45","author":"Liu","year":"2021","journal-title":"Oncol. Rep."},{"key":"ref_42","unstructured":"(2023, November 19). Oncology (Cancer)\/Hematologic Malignancies Approval Notifications, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/oncology-cancer-hematologic-malignancies-approval-notifications."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11912-020-0897-9","article-title":"Immune-related adverse events (irAEs): Diagnosis, management, and clinical pearls","volume":"22","author":"Darnell","year":"2020","journal-title":"Curr. Oncol. Rep."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"R207","DOI":"10.1530\/EC-20-0342","article-title":"Management of endocrine immune-related adverse events of immune checkpoint inhibitors: An updated review","volume":"9","year":"2020","journal-title":"Endocr. Connect."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: A systematic review and meta-analysis","volume":"4","author":"Barry","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"230ra45","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1016\/j.ajpath.2016.08.020","article-title":"Hypophysitis secondary to cytotoxic T-tymphocyte-associated protein 4 blockade: Insights into pathogenesis from an autopsy series","volume":"186","author":"Caturegli","year":"2016","journal-title":"Am. J. Pathol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1634\/theoncologist.2018-0470","article-title":"Endocrine-related adverse events related to immune checkpoint inhibitors: Proposed algorithms for management","volume":"25","author":"Cordes","year":"2020","journal-title":"Oncologist"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1210\/jc.2014-2306","article-title":"Ipilimumab-induced hypophysitis: A detailed longitudinal analysis in a large cohort of patients with metastatic melanoma","volume":"99","author":"Faje","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"R153","DOI":"10.1530\/EJE-13-0434","article-title":"Endocrine side-effects of anti-cancer drugs: mAbs and pituitary dysfunction: Clinical evidence and pathogenic hypotheses","volume":"169","author":"Torino","year":"2013","journal-title":"Eur. J. Endocrinol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1158\/1078-0432.CCR-14-2353","article-title":"Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: A retrospective cohort study","volume":"21","author":"Min","year":"2015","journal-title":"Clin. Cancer. Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1530\/EJE-17-0810","article-title":"The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma","volume":"178","author":"Scott","year":"2018","journal-title":"Eur. J. Endocrinol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1634\/theoncologist.2019-0555","article-title":"Immune checkpoint inhibitor-associated primary adrenal insufficiency: WHO VigiBase report analysis","volume":"25","author":"Grouthier","year":"2020","journal-title":"Oncologist"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1055\/a-0843-3366","article-title":"A Systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors","volume":"51","author":"Andreescu","year":"2019","journal-title":"Horm. Metab. Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e518","DOI":"10.1097\/RLU.0000000000000887","article-title":"Ipilimumab-induced adrenalitis: A possible pitfall in 18F-FDG-PET\/CT","volume":"40","author":"Bacanovic","year":"2015","journal-title":"Clin. Nucl. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1210\/js.2017-00170","article-title":"Polyendocrinopathy resulting from pembrolizumab in a patient with a malignant melanoma","volume":"1","author":"Paepegaey","year":"2017","journal-title":"J. Endocr. Soc."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"107050","DOI":"10.1016\/j.intimp.2020.107050","article-title":"Reversible primary adrenal insufficiency related to anti-programmed cell-death 1 protein active immunotherapy: Insight into an unforeseen outcome of a rare immune-related adverse event","volume":"89 Pt B","author":"Deligiorgi","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S2213-8587(13)70031-7","article-title":"Ipilimumab-induced autoimmune adrenalitis","volume":"1","author":"Min","year":"2013","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"iv264","DOI":"10.1093\/annonc\/mdy162","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Haanen","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"255","DOI":"10.6004\/jnccn.2019.0013","article-title":"Management of immunotherapy-related toxicities, version 1.2019","volume":"17","author":"Thompson","year":"2019","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s12020-021-02649-6","article-title":"Therapy options for adrenal insufficiency and recommendations for the management of adrenal crisis","volume":"71","author":"Nowotny","year":"2021","journal-title":"Endocrine"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s11154-018-9463-2","article-title":"Thyroid disorders induced by checkpoint inhibitors","volume":"19","author":"Ferrari","year":"2018","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"k793","DOI":"10.1136\/bmj.k793","article-title":"Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: Systematic review and meta-analysis","volume":"360","author":"Baxi","year":"2018","journal-title":"BMJ"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3389\/fonc.2020.00091","article-title":"Potential immune-related adverse events associated with monotherapy and combination therapy of ipilimumab, nivolumab, and pembrolizumab for advanced melanoma: A systematic review and meta-analysis","volume":"10","author":"Almutairi","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1010279","DOI":"10.3389\/fendo.2022.1010279","article-title":"Thyroid-related adverse events induced by immune checkpoint inhibitors","volume":"13","author":"Chera","year":"2022","journal-title":"Front. Endocrinol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/annonc\/mdw640","article-title":"Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer","volume":"28","author":"Osorio","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1210\/jc.2014-4560","article-title":"Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies","volume":"100","author":"Orlov","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1089\/thy.2018.0116","article-title":"Immune-related thyroiditis with immune checkpoint inhibitors","volume":"28","author":"Iyer","year":"2018","journal-title":"Thyroid"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1210\/jc.2017-00448","article-title":"Pembrolizumab-induced thyroiditis: Comprehensive clinical review and insights into underlying involved mechanisms","volume":"102","author":"Delivanis","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1089\/thy.2019.0250","article-title":"PD-L1 inhibitor-induced thyroiditis is associated with better overall survival in cancer patients","volume":"30","author":"Kotwal","year":"2020","journal-title":"Thyroid"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1111\/cas.14363","article-title":"Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors","volume":"111","author":"Kurimoto","year":"2020","journal-title":"Cancer Sci."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Yamauchi, I., Yasoda, A., Matsumoto, S., Sakamori, Y., Kim, Y.H., Nomura, M., Otsuka, A., Yamasaki, T., Saito, R., and Kitamura, M. (2019). Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0216954"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1634\/theoncologist.2015-0509","article-title":"Immune checkpoint inhibitors: Review and management of endocrine adverse events","volume":"21","year":"2016","journal-title":"Oncologist"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/IOP.0000000000001161","article-title":"Extraocular muscle enlargement and thyroid eye disease-like orbital inflammation associated with immune checkpoint inhibitor therapy in cancer patients","volume":"35","author":"Sagiv","year":"2019","journal-title":"Ophthalmic Plast. Reconstr. Surg."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"424","DOI":"10.3109\/01676830.2014.949792","article-title":"Thyroid-like ophthalmopathy in a euthyroid patient receiving ipilimumab","volume":"33","author":"McElnea","year":"2014","journal-title":"Orbit"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1159\/000485742","article-title":"Severe inflammatory ophthalmopathy in a euthyroid patient during nivolumab treatment","volume":"7","author":"Campredon","year":"2018","journal-title":"Eur. Thyroid J."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Deligiorgi, M.V., Sagredou, S., Vakkas, L., and Trafalis, D.T. (2021). The continuum of thyroid disorders related to immune checkpoint inhibitors: Still many pending queries. Cancers, 13.","DOI":"10.3390\/cancers13215277"},{"key":"ref_82","first-page":"140092","article-title":"A novel melanoma therapy stirs up a storm: Ipilimumab-induced thyrotoxicosis","volume":"2015","author":"Yu","year":"2015","journal-title":"Endocrinol. Diabetes Metab. Case Rep."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s13256-018-1708-x","article-title":"Combination therapy of ipilimumab and nivolumab induced thyroid storm in a patient with Hashimoto\u2019s disease and diabetes mellitus: A case report","volume":"12","author":"Yonezaki","year":"2018","journal-title":"J. Med. Case Rep."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"bcr2016214603","DOI":"10.1136\/bcr-2016-214603","article-title":"A rare case of thyroid storm","volume":"2016","author":"McMillen","year":"2016","journal-title":"BMJ Case Rep."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40425-017-0213-x","article-title":"Nivolumab induced myxedema crisis","volume":"5","author":"Khan","year":"2017","journal-title":"J. Immunother. Cancer."},{"key":"ref_86","first-page":"21","article-title":"Myxoedema coma caused by immunotherapy-related thyroiditis and enteritis","volume":"2021","author":"McDonald","year":"2021","journal-title":"Endocrinol. Diabetes Metab. Case Rep."},{"key":"ref_87","first-page":"8855943","article-title":"Myxedema coma: A life-threatening condition in patients using pembrolizumab","volume":"2020","author":"Gummalla","year":"2020","journal-title":"Case Rep. Endocrinol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1177\/1078155219835912","article-title":"Nivolumab-induced hypothyoidism with consequent hypothyroid related myopathy","volume":"26","author":"Johnson","year":"2020","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"625","DOI":"10.2217\/imt-2020-0053","article-title":"So slow, so fast, a case of nivolumab-induced hypothyroidism with subsequent rhabdomyolysis","volume":"12","author":"Abushalha","year":"2020","journal-title":"Immunotherapy"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2217\/imt-2017-0174","article-title":"Nivolumab-induced synchronous occurrence of myositis and hypothyroidism in a patient with squamous cell lung cancer","volume":"10","author":"Badovinac","year":"2018","journal-title":"Immunotherapy"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1158\/2326-6066.CIR-13-0146","article-title":"Anti-PD1 following ipilimumab for mucosal melanoma: Durable tumor response associated with severe hypothyroidism and rhabdomyolysis","volume":"2","author":"Min","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"e3366","DOI":"10.1002\/dmrr.3366","article-title":"Diabetes mellitus induced by immune checkpoint inhibitors","volume":"37","author":"Zheng","year":"2021","journal-title":"Diabetes Metab. Res. Rev."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1530\/EJE-19-0291","article-title":"Immune checkpoint inhibitors and type 1 diabetes mellitus: A case report and systematic review","volume":"181","author":"Pen","year":"2019","journal-title":"Eur. J. Endocrinol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1084\/jem.20022125","article-title":"The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice","volume":"198","author":"Ansari","year":"2003","journal-title":"J. Exp. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.4049\/jimmunol.1003496","article-title":"The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo","volume":"187","author":"Paterson","year":"2011","journal-title":"J. Immunol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ebiom.2018.09.040","article-title":"PDL1 is expressed in the islets of people with type 1 diabetes and is up-regulated by interferons-\u03b1 and-\u03b3 via IRF1 induction","volume":"36","author":"Colli","year":"2018","journal-title":"EBioMedicine"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1007\/s00262-017-2033-8","article-title":"Autoimmune diabetes induced by PD-1 inhibitor-retrospective analysis and pathogenesis: A case report and literature review","volume":"66","author":"Gauci","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.2337\/dbi18-0002","article-title":"Collateral damage: Insulin-dependent diabetes induced with checkpoint inhibitors","volume":"67","author":"Stamatouli","year":"2018","journal-title":"Diabetes"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"5499","DOI":"10.1210\/jc.2019-00423","article-title":"Checkpoint inhibitor-associated autoimmune diabetes is distinct from type 1 diabetes","volume":"104","author":"Tsang","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"e14788","DOI":"10.1111\/dme.14788","article-title":"The management of diabetic ketoacidosis in adults\u2014An updated guideline from the Joint British Diabetes Society for Inpatient Care","volume":"39","author":"Dhatariya","year":"2022","journal-title":"Diabet. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"7459268","DOI":"10.1155\/2020\/7459268","article-title":"Hypocalcemia with immune checkpoint inhibitors: The disparity among various reports","volume":"2020","author":"Nalluru","year":"2020","journal-title":"Int. J. Endocrinol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1007\/s12020-020-02355-9","article-title":"Mapping endocrine toxicity spectrum of immune checkpoint inhibitors: A disproportionality analysis using the WHO adverse drug reaction database, VigiBase","volume":"69","author":"Bai","year":"2020","journal-title":"Endocrine"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1186\/s40425-019-0754-2","article-title":"Endocrine toxicity of immune checkpoint inhibitors: A real-world study leveraging US Food and Drug Administration adverse events reporting system","volume":"7","author":"Zhai","year":"2019","journal-title":"J. Immunother. Cancer."},{"key":"ref_104","first-page":"269","article-title":"Endocrine dysfunction induced by immune checkpoint inhibitors","volume":"81","author":"Deligiannis","year":"2021","journal-title":"Medicina"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"dgaa092","DOI":"10.1210\/clinem\/dgaa092","article-title":"Activating antibodies to the calcium-sensing receptor in immunotherapy-induced hypoparathyroidism","volume":"105","author":"Lupi","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.aace.2020.11.003","article-title":"Pembrolizumab-associated hypoparathyroidism: A single case report","volume":"7","author":"Mahmood","year":"2020","journal-title":"AACE Clin. Case Rep."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1200\/JOP.18.00076","article-title":"Autoimmune-related primary hypoparathyroidism possibly induced by the administration of pembrolizumab: A case report","volume":"14","author":"Umeguchi","year":"2018","journal-title":"J. Oncol. Pract."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"K21","DOI":"10.1530\/EO-22-0047","article-title":"Hypoparathyroidism: An uncommon adverse effect of treatment with durvalumab","volume":"2","author":"Kreze","year":"2022","journal-title":"Endocr. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1210\/jc.2018-01151","article-title":"Immune checkpoint inhibitor-induced hypoparathyroidism associated with calcium-sensing receptor-activating autoantibodies","volume":"104","author":"Piranavan","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"e000687","DOI":"10.1136\/jitc-2020-000687","article-title":"Calcium-sensing receptor autoantibody-mediated hypoparathyroidism associated with immune checkpoint inhibitor therapy: Diagnosis and long-term follow-up","volume":"8","author":"Dadu","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.mayocpiqo.2020.07.006","article-title":"Hypoparathyroidism: An uncommon complication associated with immune checkpoint inhibitor therapy","volume":"4","author":"Li","year":"2020","journal-title":"Mayo Clin. Proc. Innov. Qual. Outcomes"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s40425-019-0528-x","article-title":"Inflammation-induced hypoparathyroidism triggered by combination immune checkpoint blockade for melanoma","volume":"7","author":"Trinh","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Mytareli, C., Ziogas, D.C., Karampela, A., Papalexis, P., Siampanopoulou, V., Lafioniatis, A., Benopoulou, O., Gogas, H., and Angelousi, A. (2023). The uncharted landscape of rare endocrine immune-related adverse events. Cancers, 15.","DOI":"10.3390\/cancers15072016"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1210\/jc.2006-2466","article-title":"The calcium-sensing receptor is a target of autoantibodies in patients with autoimmune polyendocrine syndrome type 1","volume":"92","author":"Gavalas","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Meager, A., Visvalingam, K., Peterson, P., M\u00f6ll, K., Murum\u00e4gi, A., Krohn, K., Eskelin, P., Perheentupa, J., Husebye, E., and Kadota, Y. (2006). Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1. PLoS Med., 3.","DOI":"10.1371\/journal.pmed.0030289"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa0706487","article-title":"Autoimmune polyendocrine syndrome type 1 and NALP5, a parathyroid autoantigen","volume":"358","author":"Alimohammadi","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1039.e5","DOI":"10.1016\/j.ajem.2017.02.048","article-title":"Acute symptomatic hypocalcemia from immune checkpoint therapy-induced hypoparathyroidism","volume":"35","author":"Win","year":"2017","journal-title":"Am. J. Emerg. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3803\/EnM.2021.1007","article-title":"Clinical characteristics, management, and potential biomarkers of endocrine dysfunction induced by immune checkpoint inhibitors","volume":"36","author":"Iwama","year":"2021","journal-title":"Endocrinol. Metab."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1507\/endocrj.EJ19-0163","article-title":"Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: Clinical guidelines of the Japan Endocrine Society","volume":"66","author":"Arima","year":"2019","journal-title":"Endocr. J."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-22-0689","article-title":"Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: An ESE clinical practice guideline","volume":"187","author":"Husebye","year":"2022","journal-title":"Eur. J. Endocrinol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/24\/5786\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:36:15Z","timestamp":1760132175000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/24\/5786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,10]]},"references-count":120,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["cancers15245786"],"URL":"https:\/\/doi.org\/10.3390\/cancers15245786","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,10]]}}}